Holen Sie sich die Stockscreener-App
8.58
2.26%
0.19
Handel nachbörslich:
8.58
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Quant Models Detect Momentum Reversal in BioCryst Pharmaceuticals Inc.July 2025 Trade Ideas & Technical Entry and Exit Tips - newsyoung.net
Chartists Watching For Breakout in BioCryst Pharmaceuticals Inc.2025 Technical Patterns & Verified Momentum Stock Alerts - 선데이타임즈
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call Transcript - MSN
What is BioCryst Pharmaceuticals Inc.’s TAM (Total Addressable Market)Portfolio Gains Summary & Free Weekly Chart Analysis and Trade Guides - 선데이타임즈
Is BioCryst Pharmaceuticals Inc. affected by consumer sentiment2025 Major Catalysts & Daily Price Action Insights - thegnnews.com
Is BioCryst Pharmaceuticals Inc. stock influenced by commodity pricesMarket Risk Report & Consistent Growth Stock Picks - sisa-n.com
BioCryst Director Makes a Significant Stock Sale! - TipRanks
Does BioCryst Pharmaceuticals Inc. stock reflect fundamentalsJuly 2025 Fed Impact & Daily Momentum Trading Reports - thegnnews.com
Heggie, director at Biocryst, sells $595k in shares By Investing.com - Investing.com South Africa
Heggie, director at Biocryst, sells $595k in shares - Investing.com
Why BioCryst Pharmaceuticals Inc. stock attracts strong analyst attentionWeekly Profit Analysis & Daily Profit Maximizing Trade Tips - sundaytimes.kr
Drawdown in BioCryst Pharmaceuticals Inc. May Be Nearing End2025 Bull vs Bear & Trade Opportunity Analysis - newsyoung.net
Ranking BioCryst Pharmaceuticals Inc. among high performing stocks via toolsJuly 2025 Summary & Precise Trade Entry Recommendations - Newser
Long term hold vs stop loss in BioCryst Pharmaceuticals Inc.Trend Reversal & Safe Investment Capital Preservation Plans - Newser
RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - MSN
How Efficient Is BioCryst Pharmaceuticals Inc. at Controlling Operating Costs2025 Technical Overview & High Accuracy Trade Alerts - Newser
BioCryst Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Technicals & Fast Momentum Stock Entry Tips - Newser
BioCryst (BCRX) Q2 Revenue Jumps 50% - AOL.com
Are Options Traders Betting on a Big Move in BCRX Stock? - Yahoo Finance
Will BioCryst Pharmaceuticals Inc. price bounce be sustainableReal-Time Investment Picks with Accuracy - Newser
Will BioCryst Pharmaceuticals Inc. benefit from rising consumer demandStock Picks with Accelerated Return - newsyoung.net
BioCryst’s Chief R&D Officer Resigns Amid CEO Decision - The Globe and Mail
BioCryst Announces Departure of Dr. Helen Thackray - GlobeNewswire
BioCryst Announces Departure of Dr. Helen Thackray | BCRX Stock News - GuruFocus
BioCryst’s chief R&D officer to depart for CEO role elsewhere - Investing.com
BioCryst’s chief R&D officer to depart for CEO role elsewhere By Investing.com - Investing.com Canada
BioCryst's R&D Chief Departs Following CEO Race: What This Means for ORLADEYO and 2 Pipeline Drugs - Stock Titan
New Product Launches: Will They Boost BioCryst Pharmaceuticals Inc. Stock in 2025Free Technical Stock Breakout Predictions - Newser
BioCryst’s BCX17725: A Promising Step Forward in Treating Netherton Syndrome - TipRanks
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
BioCryst (BCRX) Gets a Buy from RBC Capital - The Globe and Mail
BioCryst Pharmaceuticals 2025 Q2 Earnings Record Net Income Surges 140% - AInvest
BioCryst reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Biocryst Pharmaceuticals shares rise 1.20% premarket after reporting inducement grants under Nasdaq listing. - AInvest
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst Pharmaceuticals Receives Buy Rating from RBC Capital Analyst Brian Abrahams - AInvest
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals grants 36,700 shares of stock options and RSUs to new employees. - AInvest
BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks
BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN
BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating - TipRanks
BioCryst Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
BioCryst: Q2 Earnings Snapshot - New Haven Register
BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance
BioCryst Pharma Maintains Buy Rating with $17 Price Target - AInvest
BioCryst Pharmaceuticals Reports Record Q2 2025 Results - TipRanks
BioCryst Pharmaceuticals: A Strategic Blueprint for $1 Billion in ORLADEYO Revenue by 2027 - AInvest
BioCryst Pharmaceuticals' Q2 2025: Unpacking Contradictions in ORLADEYO Demand, Market Share, and Financial Metrics - AInvest
BioCryst Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
Transcript : BioCryst Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level - Stocktwits
BioCryst Pharmaceuticals Soars 15.35% on Strong Earnings - AInvest
Earnings call transcript: BioCryst Q2 2025 sees strong earnings beat, shares surge - Investing.com
BioCryst Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
BioCryst Pharmaceuticals Reports Impressive Q2 EarningsNews and Statistics - IndexBox
0.07%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):